By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merck Frosst Canada Ltd. 

16711 Trans Canada Highway

Kirkland  Quebec  H9H 3L1  Canada
Phone: 514-428-8600 Fax: 514-428-8645


Merck Frosst Canada Ltd. is a research-driven pharmaceutical company discovering, developing, and marketing a broad range of innovative medicines to improve human health. The Company boasts a long record of innovation and its scientific discoveries have led to medicines alleviating suffering, and prolonging and enhancing the lives of Canadians and people around the world. Increasingly, these same discoveries are contributing to the search for better ways of managing the country's scarce healthcare resources and thereby helping to safeguard one of the world's most accessible and effective healthcare systems.

The Company

Merck Frosst employs nearly 1600 people across Canada, including 1000 who work at the corporate headquarters in Montréal, Québec. Recently, Merck Frosst invested in the MaRS Centre in Toronto’s renowned downtown Discovery District. The company consistently ranks as one of the top 20 corporate R&D investors in Canada, with an investment of $114 million in 2006. Merck Frosst is a subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, which ranks among the world's leading pharmaceutical companies.

The Company is a recognized leader in the treatment of asthma, osteoporosis, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular medicines for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines.

Driven by Research

The roots of Merck Frosst are planted deep in the history of Canadian scientific research. It has invested heavily in research and development (R&D) since its beginning in 1899. The Merck Frosst Centre for Therapeutic Research is one of the largest private biomedical research facilities in Canada. More than 300 of the world's leading scientific personnel work to discover new therapeutic agents for the treatment of respiratory diseases, inflammatory diseases, diabetes, osteoporosis and hypertension. The Merck Frosst Centre for Therapeutic Research, located in Montreal, Quebec, is one of ten Merck research laboratories worldwide.

Merck Frosst scientists conduct the entire range of the research process in the company’s state-of-the-art laboratories. Basic research seeks to shed light on the fundamental mechanisms of disease. In addition to basic research, which encompasses Medicinal Chemistry, Biology, Biochemistry, Pharmacology and Molecular Biology, the Merck Frosst Centre for Therapeutic Research also has a strong development component. Promising compounds are investigated to observe their effects on these mechanisms. This investigation includes finding the correct dosage and the best means of delivering the medication. The discovered and newly synthesized chemical entities must go through the process of formulation development before first administration to man. The Merck Frosst Centre for Therapeutic Research also works extensively with scientists in universities, hospitals, healthcare institutions and our network of Merck research centres.

With the development of SINGULAIR® (montelukast sodium), the Merck Frost Centre for Therapeutic Research has earned its place as one of the world's leading research centres.

Other successes for the Merck Frosst Centre for Therapeutic Research include the discovery of the cardiovascular drug BLOCADREN® (timolol maleate tablets), the muscle relaxant FLEXERIL® (cyclobenzaprine hydrochloride) and TIMOPTIC® (timolol maleate ophthalmic solution) for glaucoma.

Last Updated: 03-19-2007

Key Statistics

Ownership: Private

Web Site: Merck Frosst Canada Ltd.
Employees: 1555


Company News
Merck Frosst Canada Ltd. Release: HPV Vaccine Prevents Genital Warts In Males; Efficacy in Preventing HPV-Related Disease in Males in Phase III Study 11/13/2008 6:55:48 AM
Canada Halts Use of Merck Frosst Canada Ltd. Mumps Vaccine, Launches Probe 12/13/2007 7:01:16 AM
Merck Frosst Canada Ltd. Release: RotaTeq(TM) Is Approved In Canada - The First And Only Vaccine In Canada To Prevent Rotavirus Gastroenteritis In Infants 8/23/2006 11:59:35 AM
Merck Frosst Canada Ltd.'s GARDASIL(TM) Now Available In Canada 8/21/2006 8:23:39 AM
Merck Frosst Canada Ltd. And Genome Quebec Announce Important Research And Development Investment 4/7/2006 1:39:49 PM
Technique May Speed Drug Production, Reduce Costs And Waste10/19/2005 5:13:13 PM
Merck Frosst Canada Welcomes Health Canada Scientific Advisory Panel On COX-2 Inhibitors10/19/2005 5:13:04 PM
Michigan Attorney General Mike Cox Announces Vioxx Consumer Refund Program10/19/2005 5:12:28 PM
Hagens Berman Release: Arizona Consumer Files First Class Action Against Vioxx Manufacturer Merck & Co., Inc. (MRK)10/19/2005 5:12:26 PM
Xenogen Corporation (XGEN) Announces Five-Year Global Licensing Agreement With Merck & Co. (MRK)10/19/2005 5:11:49 PM